CCMG
AZN icon

Clark Capital Management Group’s AstraZeneca AZN Stock Holding History

Clark Capital Management Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115M Buy
608,068
+8,016
+1% +$1.51M 0.63% 35
2026
Q1 		$118M Sell
600,052
-46,533
-7% -$8.97M 0.73% 29
2025
Q4 		$119M Sell
646,585
-657
-0.1% -$115K 0.73% 32
2025
Q3 		$99.3M Buy
647,242
+313,985
+94% +$47.5M 0.62% 40
2025
Q2 		$46.6M Buy
333,257
+137,672
+70% +$19.3M 0.32% 113
2025
Q1 		$28.8M Buy
195,585
+190,561
+3,793% +$27.6M 0.21% 133
2024
Q4 		$658K Buy
5,024
+2,369
+89% +$332K ﹤0.01% 323
2024
Q3 		$414K Sell
2,655
-67
-2% -$10.8K ﹤0.01% 341
2024
Q2 		$425K Buy
2,722
+148
+6% +$22.3K ﹤0.01% 324
2024
Q1 		$349K Sell
2,574
-214
-8% -$28.3K ﹤0.01% 347
2023
Q4 		$375K Buy
2,788
+224
+9% +$29.1K ﹤0.01% 332
2023
Q3 		$347K Sell
2,564
-74
-3% -$10.1K ﹤0.01% 303
2023
Q2 		$378K Sell
2,638
-140
-5% -$20.6K ﹤0.01% 305
2023
Q1 		$386K Sell
2,778
-165,495
-98% -$22.3M ﹤0.01% 299
2022
Q4 		$22.8M Buy
168,273
+6,065
+4% +$761K 0.21% 141
2022
Q3 		$17.8M Sell
162,208
-64,027
-28% -$8.12M 0.23% 149
2022
Q2 		$29.9M Sell
226,235
-136,776
-38% -$17.9M 0.39% 67
2022
Q1 		$48.2M Buy
363,011
+8,570
+2% +$1.03M 0.54% 40
2021
Q4 		$41.3M Sell
354,441
-291,411
-45% -$34.3M 0.51% 63
2021
Q3 		$77.6M Buy
645,852
+145,125
+29% +$16.9M 1.06% 16
2021
Q2 		$60M Buy
500,727
+183,647
+58% +$20.1M 0.84% 23
2021
Q1 		$31.5M Sell
317,080
-18,508
-6% -$1.86M 0.48% 75
2020
Q4 		$33.6M Buy
+335,588
New +$35.5M 0.55% 52

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Clark Capital Management Group's AZN Position: Q2 2026 in Review

Clark Capital Management Group increased its AstraZeneca (AZN) stake by 1.3% in Q2 2026, buying an estimated $1.51M and bringing the position to 608,068 shares worth $115M. The position accounts for 0.63% of the portfolio, ranked #35.

Clark Capital Management Group first reported a position in AZN in Q4 2020 and has held it in 23 quarters since. The position peaked at $119M in Q4 2025. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Clark Capital Management Group held 608,068 shares of AstraZeneca worth $115M as of Q2 2026.
  • Clark Capital Management Group bought 8,016 AstraZeneca shares in Q2 2026, an estimated $1.51M.
  • AstraZeneca made up 0.63% of Clark Capital Management Group's portfolio in Q2 2026, its #35 holding.
  • Clark Capital Management Group first reported a position in AstraZeneca in Q4 2020 and has held it in 23 quarters since.
  • Clark Capital Management Group's AstraZeneca position peaked at $119M in Q4 2025.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.